[Are] psychedelics… making a comeback…
The increasing success of FDA-approved cannabinoid therapeutics helps drive the interest in psychedelics. ClinicalTrials.gov lists more than 400 trials involving cannabinoids. As its effectiveness is shown, the compound gains traction within the pharmaceutical industry as a possible active ingredient in a variety of therapeutics.
“We were fortunate to watch the cannabis industry grow into a sustainable marketplace for both medicinal and recreational use,” said Vanessa Luna, CEO of PSYC. “We will be embarking on the same path for psychedelic medicine by engaging with industry experts, which will likely expand to a new advisory board and a more defined approach,” she continued. “That, in turn, likely will result in a unique plan to engage this market.” She did not elaborate.
Original Article (Biospace):
Psychedelics make a comeback as therapies for brain injury, PTSD, anxiety and even addiction
Artwork Fair Use: Pixel.la